Medizone International Announces It Will Move Forward With Human Clinical Trials Salt Lake City, UT - October 21, 1997, - Medizone International, Inc. ("Medizone") (OTC.BB:MZEI.U) announced today it has reached an agreement in principle to commence Phase I/II Human Clinical Trials at two prestigious Italian University sites using Medizone patented "thin-film" ozone technology. The clinical trials will test the safety, toxicity and efficacy of Medizone's patented "thin-film" ozone technology against the HIV virus in adults and children. Medizone President and Chief Operating Officer, Milton G. Adair, and the Company's Director of Research and Development, Gerard V. Sunnen, M.D., will travel to Italy the week of November 10, 1997 to finalize the details of the agreements with Dr. Mariano Franzini, Professor at the University of Pavia and President of the Italian Scientific Society for Oxygen-Ozone Therapy ("ISSOT") who, as required by law, acts as an onsite coordinator. They will also meet with study site coordinators, DRS. Carlo Giaquinto and Umberto Tirelli. Dr. Giaquinto is a Professor at the Departimento di Pediatria, Universita di Padova Universita Hospital. Dr. Tirelli serves as Chief, Division of Oncology and AIDS at the National Cancer Center, Aviano, Italy. Once the final agreements are signed and the protocols approved, patient enrollment will begin It is anticipated that the trials will commence during the first quarter of 1998. Medizone's Chairman of the Board, Edwin Marshall stated, "I'm extremely pleased with the energy and focus of our new management team. Moving forward with our research efforts is clearly the best use of our financial resources while providing us the opportunity to validate the patented Medizone "thin-film" technology." Medizone International, Inc., is a research and development stage company engaged in the development of an ozone-based treatment for diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B and Herpes; and in the development of its patented technology for the decontamination of blood and blood products. For information, call CTC inc., (937) 434-2700 or Medizone International, Inc. (801) 274-8400 or visit our web site at www.medizoneint.com.